- Home
- HHH vs AMLX Comparison
HHH vs AMLX Comparison
Compare HHH & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHH | AMLX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.8B |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HHH | AMLX |
|---|---|---|
| Price | $69.50 | $28.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $84.00 | $43.00 |
| AVG Volume (30 Days) | 688.6K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 2.82 | N/A |
| Revenue | ★ $1,474,892,000.00 | $380,786,000.00 |
| Revenue This Year | $70.68 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.43 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $60.09 | $10.83 |
| 52 Week High | $91.07 | $41.14 |
Technical Indicators
Market Signals| Indicator | HHH | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 50.90 |
| Support Level | $61.79 | $12.97 |
| Resistance Level | $74.76 | $34.35 |
| Average True Range (ATR) | 2.08 | 1.28 |
| MACD | -0.54 | 0.22 |
| Stochastic Oscillator | 40.42 | 73.48 |
Price Performance
Historical ComparisonAbout HHH Howard Hughes Holdings Inc.
Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.